News

Proposed Bevacizumab Biosimilar BAT1706 Found Equivalent to Reference Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer

11/22/2023

Allison Casey

According to a phase 3 trial, the proposed bevacizumab biosimilar BAT1706 was found equivalent to reference biosimilar for the treatment of patients with advanced nonsquamous non-small cell lung cancer.

According to a phase 3 trial,...

11/22/2023

Oncology

News

Pertuzumab Biosimilar QL1209 Demonstrated Equivalent Efficacy, Safety to Reference Pertuzumab Among Patients With HER2-Positive Breast Cancer

11/06/2023

Allison Casey

According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.

According to a phase 3 study,...

11/06/2023

Oncology

News

Bevacizumab Biosimilar Efficacy, Safety for Patients With Metastatic Colorectal Cancer

10/10/2023

Allison Casey

According to real-world data, the bevacizumab biosimilar, bevacizumab-awwb, was found to be as effective and safe as the bevacizumab reference product for patients with metastatic colorectal cancer.

According to real-world data,...

10/10/2023

Oncology

News

Docetaxel-PM Plus Trastuzumab Biosimilar Showed Antitumor Activity Among Patients With HER2-Positive Salivary Duct Carcinoma

10/10/2023

Allison Casey

According to a phase 2 trial, combination docetaxel-PM and trastuzumab-pkrb demonstrated antitumor activity among patients with HER2-positive salivary duct carcinoma.

According to a phase 2 trial,...

10/10/2023

Oncology

News

Patients Report Satisfaction With Biosimilar Treatment, But Demonstrate Lack of Overall Knowledge

09/11/2023

Allison Casey

According to a systematic review, patients are satisfied with biosimilar treatments but have limited knowledge about biosimilars, a lack of which can affect their perceptions of the clinical effects and regulation process.

According to a systematic...

09/11/2023

Oncology

News

09/07/2023

Gina Tomaine

The rituximab biosimilar, SDZ-RTX, combined with a CHOP regimen was effective and well-tolerated as a frontline treatment for patients with diffuse large B-cell lymphoma (DLBCL), according to a real-world study.

The rituximab biosimilar,...

09/07/2023

Oncology

News

Serplulimab Plus Bevacizumab Biosimilar Showed Efficacy, Safety Among Patients With Hepatocellular Carcinoma

09/05/2023

Allison Casey

According to a results from a phase 2 study, serplulimab plus HLX04, a bevacizumab biosimilar, showed promising antitumor activity and manageable safety among patients with previously treated advanced hepatocellular carcinoma.

According to a results from a...

09/05/2023

Oncology

News

Trastuzumab Biosimilar Plus Paclitaxel Shows Promise for Patients With HER2-Positive Recurrent or Metastatic Urothelial Carcinoma

08/04/2023

Allison Casey

In a phase 2 trial, the trastuzumab biosimilar, trastuzumab-pkrb, plus paclitaxel demonstrated promising efficacy and manageable toxicity among patients with HER2-positive urothelial carcinoma.

In a phase 2 trial, the...

08/04/2023

Oncology

News

Bevacizumab Biosimilar Demonstrated Similar Efficacy, Safety as Reference Product Among Patients With Metastatic Colorectal Cancer

07/31/2023

Allison Casey

The bevacizumab biosimilar, bevacizumab-awwb, was effective and well-tolerated in the first-line setting among patients with metastatic colorectal cancer.

The bevacizumab biosimilar,...

07/31/2023

Oncology

News

Bevacizumab Biosimilar Candidate TAB008 Comparable to Reference Bevacizumab for Patients With Locally Advanced, Metastatic EGFR Wild-Type Non-Squamous NSCLC

07/10/2023

Gina Tomaine

In a phase 3 study, biosimilar candidate TAB008 was found to be similar to reference bevacizumab in terms of efficacy and safety for patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer.

In a phase 3 study, biosimilar...

07/10/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology